Benzinga’s Top Pre-Market Gainers (ARQL, AIXG, ISIS, ORCT)

ArQule, Inc. (NASDAQ: ARQL) rose 32.57% to $4.64 in the pre-market session. ArQule, Inc. announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival (PFS) in patients with advanced, refractory non-small cell lung cancer (NSCLC). The 52-week trading range for ARQL is $2.97 - $6.38. In the last six months, ARQL has declined over 22%.

Aixtron AG (ADR) (NASDAQ: AIXG) moved up 2.28% to $35.85 in the pre-market session. The 52-week trading range for AIXG is $4.98 - $38.34. Aixtron AG (ADR) closed at $35.05 in the previous trading session. AIXG has gained over 28% in the last six months.
ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) climbed 6.80% to $11 in the pre-market session.

GlaxoSmithKline (NYSE: GSK) and Isis Pharmaceuticals announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness. In the previous trading session, ISIS closed at $10.30. ISIS has declined over 31% in the last year.

Orckit Communications Ltd (NASDAQ: ORCT) jumped 2.64% to $4.27 in the pre-market session. The 52-week trading range for ORCT is $2.04 -$5.81. Orckit Communications closed at $4.16 in the last trading session. In the last year, ORCT has gained over 85%.